7 percent Endovascularsales increased 22

Diagnostics $231 8.8 -International Diagnostics$665 2.9(4.3)Worldwide Vascular Sales $66358.9(2.8)U.S. Vascular$396 102.3 -International Vascular $26720.5(5.2)Other Sales$464 (17.4) (2.2)Note:See "Consolidated Statement of Earnings" for more information.The following is a summary of sales for the full-year 2008.Impact ofSales Summary - FY08 ChangeExchangeTwelve Months Ended 12/31/08($ millions)vs FY07on ChangeTotal Sales $29,52813.9 3.2Total U.S. Sales$14,17010.1 -Total International Sales $15,35817.8 6.3Worldwide Pharmaceutical Sales$16,70814.2 3.2U.S. Pharmaceuticals $8,497 8.9 -International Pharmaceuticals$8,21120.3 6.9Worldwide Nutritional Sales$4,92412.2 1.9U.S.

Nutritionals$2,479 5.6 -International Nutritionals $2,44519.8 4.0Worldwide Diagnostics Sales$3,57513.2 5.1U.S. Vascular$1,20539.6 -International Vascular $1,03629.4 7.2Other Sales$2,080 0.3 2.6Note:See "Consolidated Statement of Earnings" for more information.The following is a summary of Abbott's fourth-quarter 2008 sales forselected products.Quarter Ended 12/31/08PercentPercentPercent(dollars inU.S ChangeRest of Change GlobalChange millions)Salesvs 4Q07World vs 4Q07Salesvs. 4Q07Pharmaceutical ProductsHUMIRA$75142.4$60040.5 a $1,35141.6TriCor/TRILIPIX $45516.0 $45516.0Kaletra $152(0.7) $226 3.5 b $378 1.8Depakote$244 (43.8)$24 (9.1) $268 (41.8)Niaspan $22123.8 $22123.8Lupron$147 n/m $66(9.6)c $213 n/mUltane/Sevorane$5815.7$140(6.8)d$198 (1.2)Biaxin (clarithromycin) $3 n/m$151 (17.8)e $154 (22.6)Synthroid $120(9.4)$227.4$142(7.1)Nutritional ProductsPediatric Nutritionals $333 2.5$39029.4 f $72315.4Adult Nutritionals$295 5.3$270 0.2 g $565 2.8Medical ProductsAbbott Diabetes Care $144 7.1$193(3.5)h $337 0.7Coronary Stents $267 245.9$14335.5 i $410 124.5Other Coronary $7215.0 $83 3.1 j $155 8.3Endovascular $57 1.3 $4115.3 k$98 6.7a Without the negative impact of exchange of 9.3 percent, HUMIRA salesincreased 49.8 percent internationally.b Without the negative impact of exchange of 4.9 percent, Kaletra salesincreased 8.4 percent internationally.c Without the negative impact of exchange of 7.5 percent, Lupron salesdecreased 2.1 percent internationally.d Without the negative impact of exchange of 6.2 percent, Sevorane salesdecreased 0.6 percent internationally.e Without the negative impact of exchange of 2.3 percent, clarithromycinsales decreased 15.5 percent internationally.f Without the negative impact of exchange of 1.3 percent, PediatricNutritionals sales increased 30.7 percent internationally.g Without the negative impact of exchange of 4.6 percent, AdultNutritionals sales increased 4.8 percent internationally.h Without the negative impact of exchange of 5.9 percent, Abbott DiabetesCare sales increased 2.4 percent internationally.i Without the negative impact of exchange of 5.2 percent, Coronary Stentssales increased 40.7 percent internationally.j Without the negative impact of exchange of 4.5 percent, Other Coronarysales increased 7.6 percent internationally.k Without the negative impact of exchange of 6.7 percent, Endovascularsales increased 22.0 percent internationally.n/m Not meaningfulThe following is a summary of Abbott's full-year 2008 sales for selectedproducts.Twelve Months Ended 12/31/08 Percent Percent Percent(dollars in U.S ChangeRest of ChangeGlobalChange millions) Salesvs FY07World vs FY07Salesvs. FY07Pharmaceutical ProductsHUMIRA$2,25536.6$2,26660.4 a $4,52147.6Kaletra $513(4.7) $96122.1 b $1,47411.2Depakote$1,262 (14.8) $1027.4$1,364 (13.4)TriCor/TRILIPIX $1,34110.1 $1,34110.1Ultane/Sevorane $193(3.4) $594 6.2 c $787 3.7Niaspan $78619.4 $78619.4Biaxin (clarithromycin)$14 n/m$637(7.4)d $651 (10.1)Lupron$377 n/m$274 6.5 e $651 n/mSynthroid $435(5.0)$89 19.2$524(1.6)Nutritional ProductsPediatric Nutritionals $1,268 2.8$1,37425.7 f $2,64213.6Adult Nutritionals $1,162 7.8$1,07013.0 g $2,23210.3Medical ProductsAbbott Diabetes Care $559 1.1$79414.2 h $1,353 8.4Coronary Stents $669 118.5$53044.8 i $1,19978.4Other Coronary$298(0.5) $34413.4 j $642 6.5Endovascular$238(7.6) $16224.1 k $400 3.1a Without the positive impact of exchange of 9.7 percent, HUMIRA salesincreased 50.7 percent internationally.b Without the positive impact of exchange of 6.7 percent, Kaletra salesincreased 15.4 percent internationally.c Without the positive impact of exchange of 5.0 percent, Sevorane salesincreased 1.2 percent internationally.d Without the positive impact of exchange of 6.2 percent, clarithromycinsales decreased 13.6 percent internationally.e Without the positive impact of exchange of 6.1 percent, Lupron salesincreased 0.4 percent internationally.f Without the positive impact of exchange of 3.6 percent, PediatricNutritionals sales increased 22.1 percent internationally.g Without the positive impact of exchange of 4.5 percent, AdultNutritionals sales increased 8.5 percent internationally.h Without the positive impact of exchange of 7.1 percent, Abbott DiabetesCare sales increased 7.1 percent internationally.i Without the positive impact of exchange of 8.0 percent, Coronary Stentssales increased 36.8 percent internationally.j Without the positive impact of exchange of 6.4 percent, Other Coronarysales increased 7.0 percent internationally.k Without the positive impact of exchange of 7.0 percent, Endovascularsales increased 17.1 percent internationally.n/m Not meaningful Business Highlights Abbott to Acquire Advanced Medical Optics (AMO) - Abbott announcedan agreement to acquire AMO, an established global leader in thelarge and growing eye care market. This acquisition strengthens andexpands Abbott's current medical device business, providing furtherdiversification for the long term. AMO participates in threesegments: cataract surgery, refractive surgery, or LASIK laservision correction, and eye care products, such as contact lenssolutions. AMO holds the number-one market position in LASIK, thenumber-two position in cataract surgery and the number-threeposition in eye care products.

The ophthalmology market is supportedby strong demographic trends, including a large population of people60 years of age and older, and increased demand for advanced visioncare procedures and products Abbott Receives FDA Approval for TRILIPIX(TM) - The U.S. FDAapproved Abbott's TRILIPIX (fenofibric acid), the first fibrate tobe approved for use in combination with a statin. The FDA approvalof TRILIPIX was based on the largest clinical trial program designedto evaluate the efficacy and safety of a fibrate in combination withvarious statins Abbott Begins U.S. The 2.25 mm stent system, to be called Xience Nano(TM) inthe United States upon FDA approval, would offer physicians anoption for treating coronary artery disease in narrower vessels thatis based on the proven efficacy, safety and deliverability of XIENCEV.